Business Update - VOQUEZNA has achieved significant progress in clinical superiority, brand awareness, and patient access during its launch phase[10] - As of April 26, 2024, over 43,000 prescriptions have been written and over 17,500 prescriptions have been filled for VOQUEZNA[12] - VOQUEZNA has secured commercial coverage for approximately 72 million lives[13] - The company is preparing for a potential Non-Erosive GERD launch, with an action date of July 19, 2024, targeting a market of approximately 15 million adults[14] Commercial Launch Progress - Total VOQUEZNA demand includes over 43,000 unique prescriptions written and over 17,500 filled prescriptions[21] - The number of unique VOQUEZNA writers has reached over 3,800[21] - There has been consistent monthly growth in filled prescriptions, reaching approximately 7,520 as of April 26, 2024[26] - Commercial coverage has expanded to 48%, covering approximately 72 million lives, including Cigna Healthcare with over 9 million lives covered[28] Financial Results - Net revenues for Q1 2024 were $1.9 million[36] - Non-GAAP SG&A expenses for Q1 2024 were $57.6 million[40] - The company reported $322.2 million in cash and cash equivalents as of March 31, 2024, which is expected to fund operations through the end of 2026[43]